Blocking CD62L inhibits CLL cell interaction with vascular endothelium; an effect that is augmented by ibrutinib

C Shere1, TN Hartmann2, G Pratt3, C Fegan1, C Pepper1, EJ Walsby1

1CLL Research Group, Division of Cancer and Genetics, School of Medicine, Cardiff University, UK; 2Laboratory for Immunological and Molecular Cancer Research, Third Medical Department, Paracelsus Medical University, Salzburg, Austria; 3Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, UK